Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Stems Q2 Losses While Hunting for Products and Partners

NEW YORK (GenomeWeb News) — Compugen yesterday reported it earned no revenues for the second quarter of 2007, while R&D spending was down 15 percent and net loss was cut 11 percent.
 
The company reported $5,000 in revenue for the second quarter of 2006.           .
 
Compugen said R&D spending in the quarter dipped to $2.3 million from $2.7 million year over year.
 
Net loss was lowered slightly to $3.2 million from $3.6 million over the same quarter last year.
 
As of June 30, Compugen had $18.8 million in cash, cash equivalents, deposits, and marketable securities.
 
Compugen CEO Alex Kotzer said the company saw “significant progress” in “product candidate development, negotiations for new licensing agreements, new engine creation and discovery validation.”
 
Kotzer said Compugen is focused on developing a “discovery engine” targeted at identifying existing drug molecules that have “important, but currently unknown, therapeutic indications.”

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.